The epidemiology of venous thromboembolism in the community: Implications for prevention and management

Journal of Thrombosis and Thrombolysis

Volumn 21, Issue 1, 2006, Pages 23-29

  Heit, John A ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Deep vein thrombosis; Epidemiology; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ASPARAGINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; TAMOXIFEN; THALIDOMIDE;

AGE; ANTICOAGULANT THERAPY; BODY MASS; CANCER; CANCER CHEMOTHERAPY; CHRONIC LIVER DISEASE; CHRONIC LUNG DISEASE; COMMUNITY CARE; COMPRESSION THERAPY; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FAMILIAL DISEASE; GENETIC PREDISPOSITION; GENETIC RISK; HEREDITY; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INNATE IMMUNITY; LUNG EMBOLISM; NERVE PARALYSIS; NEUROLOGIC DISEASE; NURSING HOME; PACEMAKER; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SUDDEN DEATH; SURGICAL RISK; SURVIVAL RATE; SYNCOPE; ULCER; UNITED STATES; VARICOSIS; VEIN CATHETERIZATION; VENOUS STASIS; VENOUS THROMBOEMBOLISM;

EPILEPSY, TONIC-CLONIC; HUMANS; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 32544431531     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-5572-y     Document Type: Review

References (96)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-593.
2. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998;128:737-740.
3. Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Card 2000;85(11):1334-1337.
4. Stein PD, Kayali F, Olson RE, Milford CE. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States. Am J Med 2004;116:435-442.
5. Hooper WC, Holman RC, Heit JA, Cobb N. Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb Res 2002;108(5-6):273-278.
6. Stein PD, Kayali F, Olson RE, Milford CE. Pulmonary thromboembolism in American Indians and Alaskan Natives. Arch Intern Med 2004;164:1804-1806.
7. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age; impact of an aging population. Arch Intern Med 2004; 164:2260-2265.
8. Cushman, M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: The Longitudinal Investigation of Thromboembolism Etiology. Am J Med 2004;117:19-25.
9. Massicote MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998;133:770-776.
10. Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: A prospective cohort study. Blood 2002;100(7):2403-2405.
11. van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HSA, Peters M. Venous thromboembolism in childhood: A prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-681.
12. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 1999;159:445-453.
13. Goldhaber SZ, Visani L, De Rosa M, for ICOPER. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389.
14. Janata K, Holzer M, Domanovits H, et al. Mortality of patients with pulmonary embolism. Wiener Klinische Wochenschrift 2002;114(17-18):766-772.
15. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry. Circulation 1997;96:882-888.
16. Pruszczyk P, Bochowicz A, Torbicki A, et al. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 2003;123:1947-1952.
17. Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003;107(12):1576-1578.
18. Wan S, Quinlan DJ, Agnelli G, Eikelboom JS. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: A meta-analysis of the randomized controlled trials. Circulation 2004;110:755-759.
19. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-1150.
20. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton, III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 2000;160:761-768.
21. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398.
22. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340(12):901-907.
23. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
24. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-169.
25. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001;103:2453-2460.
26. van Dongen CJJ, Vink R, Hutten BA, Büller HR, Prins MH. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event; a meta-analysis. Arch Intern Med 2003;163:1285-1293.
27. Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism: The Austrian Study on Recurrent Venous Thromboembolism. Wiener Klinische Wochenschrift 2003;115(13-14):471-474.
28. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558-2563.
29. Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2004;2:2152-2155.
30. Hansson P-O, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med 2000;160:769-774.
31. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
32. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125(1):1-7.
33. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362(9383):523-526.
34. Schulman S, Svenungsson E, Granqvist S, and the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998;104:332-338.
35. van den Belt AGM, Sanson B-J, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Inter Med 1997;157:227-232.
36. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137(12): 955-960.
37. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002;88:407-414.
38. Heit JA, Farmer SA, Petterson TM, Ballman KV, Melton LJ III. Venous Thromboembolism Event Type (PE±DVT vs. DVT Alone) Predicts Recurrence Type and Survival. Blood 2002;100(11):149a (abstract# 560).
39. Heit JA, Rooke TW, Silverstein MD, et al. Trends in the incidence of venous stasis syndrome and venous ulcer: A 25-year population-based study. J Vasc Surg 2001;33:1022-1027.
40. Mohr DN, Silverstein MD, Heit JA, Petterson TM, O'Fallon WM, Melton LJ III. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: A population-based study. Mayo Clin Proc 2000;75:1249-1256.
41. Dunn WF, Heit JA, Farmer SA, Petterson TM, Ballman KV. The incidence of chronic thromboembolic pulmonary hypertension (CTEPH): A 21-year population-based study (Abstract P2927). European Respiratory Society 13th Annual Congress 2003.
42. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000;160:809-815.
43. Samama M-M for the Sirius Study Group. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients. Arch Intern Med 2000;160:3415-3420.
44. Kobbervig CE, Heit JA, Petterson TM, Bailey KR, Melton LJ III. The effect of patient age on the incidence of idiopathic vs. secondary venous thromboembolism: A population-based cohort study (abstract 3516). Blood 2004;104(11):957a.
45. Heit JA, Melton LJ I, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients versus community residents. Mayo Clin Proc 2001;76:1102-1110.
46. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med 2002;162:1245-1248.
47. Geerts WH, Pineo GF, Heit JA, et al. Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 338S-400S.
48. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90:446-455.
49. White RH, Gettner S, Newman JM, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000;343:1758-1764.
50. Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology 2003;99(3):552-560.
51. Sharrock NE, Haas SB, Hargett MJ, Urguhart B, Insall JN, Scuderi G. Effects of epidural anesthesia on the incidence of deep vein thrombosis after total knee replacement. J Bone Joint Surg 1991;73A:502-506.
52. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness. Arch Intern Med 2004;164:963-968.
53. Heit JA, Petterson TM, Bailey KR, Melton LJ III. The influence of tumor site on venous thromboembolism risk among cancer patients: A population-based study (abstract 2596). Blood 2004;104(11):711a.
54. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Medicine (Baltimore) 1999;78:285-291.
55. Dalen J. Economy class syndrome; too much flying or too much sitting? Arch Intern Med 2003;163:2674.
56. Ray JG, Mamdani M, Tsuyuki RT, Anderson DA, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001;161:1405-1410.
57. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003;348(15):1435-1441.
58. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence. Arch Intern Med 2002;162:1182-1189.
59. Petterson TM, Agmon Y, Meissner I, Khandheria BK, Heit JA. Atherosclerosis as a risk factor for venous thromboembolism: A population-based cohort study (abstract 2584). Blood 2004;104(11):708a.
60. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 2004;164:1965-1976.
61. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-619.
62. Key NS, McGlennen RC. Hyperhomocyst(e)inemia and thrombophilia. Arch Path Lab Med 2002;126:1367-1375.
63. Tsai AW, Cushman M, Tsai MH, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 2003;72:192-200.
64. Souto J, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet 2000;67(6):1452-1459.
65. Larsen TB, Sorensen HT, Skytthe A, Johnsen SP, Vaupel JW, Christensen K. Major genetic susceptibility for venous thromboembolism in men: A study of Danish twins. Epidemiology 2003;14(3):328-332.
66. Heit JA, Phelps MA, Ward SA, Slusser J, Petterson TM, de Andrade M. Familial segregation of venous thromboembolism. J Thromb Haemost 2004;2:731-736.
67. Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: A prospective cohort study. Blood 1999;94(11):3702-3706.
68. Folsom AR, Aleksic N, Wang N, Cushman M, Wu KK, White RH. Protein C, antithrombin, and venous thromboembolism incidence; a prospective population-based study. Arterioscler Thromb Vasc Biol 2002;22:1018-1022.
69. Folsom AR, Cushman M, Tsai MY, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 2002;88:2720-2725.
70. Juul K, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004;140:330-337.
71. Heit JA, Sobell JL, Li H, Sommer SS. The incidence of venous thromboembolism in Factor Leiden carriers: A population-based cohort study. J Thromb Haemost 2005;3(2):305-311.
72. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003;1(12):2677-2678.
73. Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 2002;71:285-290.
74. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-155.
75. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-3682.
76. Meijers JCM, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696-701.
77. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004;104:3631-3634.
78. Folsom AR, Cushman M, Heckbert SR, Rosamond WD, Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol 2003;56:598-603.
79. Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003;101:1243-1248.
80. Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005;105:1102-1105.
81. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: The Leiden Thrombophilia Study. J Thromb Haemost 2004;2:619-622.
82. Souto J, Almasy L, Borrell M, et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101(13):1546-1551.
83. de Lange M, Snieder H, Ariëns RA, Spector TD, Grant PJ. The genetics of haemostasis: A twin study. Lancet 2001;357(9250):101-105.
84. Ariëns R, de Lange M, Snieder H, Boothby M, Spector T, Grant P: Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 2002;359:667-671.
85. Vossen CY, Hasstedt SJ, Rosendaal FR, et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004;2:242-247.
86. Morange PE, Tregouet DA, Frere C, et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Brit J Haematol 2004;128:91-99.
87. van Hylckama Vlieg A, Rosendaal FR. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. J Thromb Haemost 2003;1: 2186-90.
88. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002;87(5):791-795.
89. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580.
90. Lindahl TL, Lundahl TH, Nilsson L, Anderson CA. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee-a prospective study. Thromb Haemost 1999;81:18-21.
91. Libourel EJ, Bank I, Meinardi JR, et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 2002;87:1068-1073.
92. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H: The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210a allele in the prothrombin gene. Thromb Haemost 1999;81(5):684-689.
93. Meinardi JR, Middeldorp S, de Kam PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Brit J Haematol 2002;116:625-631.
94. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. New Engl J Med 2000;343:457-462.
95. Weltermann A, Eichinger S, Bialonczyk C, et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2003;1(1): 28-32.
96. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003;290(8):1071-1074.